ViiV Healthcare
Five Moore Drive
Research Triangle Park
North Carolina
27709-3398
United States
Tel: 877-844-8872
Website: http://www.viivhealthcare.com/
135 articles about ViiV Healthcare
-
FDA approved ViiV Healthcare’s Cabenuva as the very first once-a-month injection for HIV treatment. But the Research Triangle pharma isn’t satisfied yet.
-
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
7/17/2021
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, presented positive findings from the CUSTOMIZE trial.
-
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
7/17/2021
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, presented 48-week data from the SALSA study at the International AIDS Society Conference 2021, being held virtually 18-21 July.
-
Halozyme revealed that ViiV will pay $40 million upfront for the exclusive license to four small and large molecule targets and then pay the remaining $175 million in milestones.
-
HIV Epidemic: 40 Years Later
6/4/2021
On June 5, the world marks the 40th anniversary of the HIV epidemic. Biopharma researchers continue to develop safe and effective treatments with an eye to a potential cure. -
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
5/4/2021
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced the initiation of a rolling submission of a new drug application (NDA) with the US Food and Drug Administration (FDA) for investigational, long-acting, injectable cabotegravir for the prevention of HIV
-
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months
2/24/2021
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months
-
The drug, a combination of cabotegravir and rilpivirine, is a complete therapy for HIV-1 infection in adults who are virologically suppressed.
-
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
1/21/2021
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention
11/17/2020
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for long-acting, injectable cabotegravir for HIV pre-exposure prophylaxis (PrEP). The Breakthrough Therapy Designation was based on efficacy and safety results from HP
-
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women
11/9/2020
Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every two months is 89% more effective than daily pills in preventing HIV acquisition in women
-
The pre-specified interim data analysis indicated that the Cabotegravir hit the primary objective of superiority compared to the current standard of care for women.
-
BioSpace Global Roundup, Oct. 22
10/22/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
ViiV Healthcare Announces Availability of CABENUVA and VOCABRIA in Canada
9/23/2020
Today, ViiV Healthcare Canada announced stock availability of CABENUVA and VOCABRIA across the country. CABENUVA is the first and only once-monthly, complete long-acting injectable regimen indicated for the treatment of HIV-1 infection in adults to replace the current antiretroviral (ARV) regimen in patients who are virologically stable and
-
Clinical Catch-Up: August 17-21
8/24/2020
It was a relatively quiet week for clinical trial news. Here’s a look. -
ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1
8/6/2020
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Dovato (dolutegravir/lamivudine) as a complete regimen for the treatment of HIV-1 infection
-
Clinical Catch-Up: July 6-10
7/13/2020
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates. -
ViiV Healthcare announced an injection of cabotegravir given every two months was 66% more effective at preventing HIV infection when compared to Gilead Sciences’ Truvada, according to the final analysis of the HPTN-083 study.